Drug Search Results
More Filters [+]

Cefpirome

Alternative Names: cefpirome
Latest Update: 2023-09-12
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Bangladesh | Brazil | Bulgaria | China | Dominican Republic | Egypt | India | Indonesia | Ireland | Italy | Korea | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Slovenia | South Africa | Sri Lanka | Taiwan | Tunisia | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Med. Univ. Wien, Uk für Innere Medizin I
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cefpirome

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Abscess

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2011-002758-29

P4

Completed

Unknown

2013-10-04

abscess-cef-moxi

P4

Completed

Abscess

2009-12-01

Recent News Events